Clinical trial
Risedronate in the Prevention of Osteoporosis in Postmenopausal Women
NCT00402441 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00402441 |
|---|---|
| Title | Risedronate in the Prevention of Osteoporosis in Postmenopausal Women |
| Official title | A One-Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Efficacy and Safety of 35-mg Risedronate Administered Once a Week in the Prevention of Osteoporosis in Postmenopausal Women |
| Lead sponsor | Sanofi, Industry |
| Collaborators | Procter and Gamble Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Osteoporosis, Postmenopausal |
| Intervention type | Drug |
| Interventions | Risedronate (HMR4003) |
| Enrollment | 260 |
| Start date | Sep 1, 2002 |
| Primary completion | Jun 1, 2004 |
| Completion | Jun 1, 2004 |
| First posted | Nov 22, 2006 |
| Last update posted | Apr 29, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: